MDT

86.75

+0.53%↑

A

120.69

+2.16%↑

VEEV

170.52

+0.75%↑

HQY

85.25

+2.3%↑

NEOG

9.47

+1.61%↑

MDT

86.75

+0.53%↑

A

120.69

+2.16%↑

VEEV

170.52

+0.75%↑

HQY

85.25

+2.3%↑

NEOG

9.47

+1.61%↑

MDT

86.75

+0.53%↑

A

120.69

+2.16%↑

VEEV

170.52

+0.75%↑

HQY

85.25

+2.3%↑

NEOG

9.47

+1.61%↑

MDT

86.75

+0.53%↑

A

120.69

+2.16%↑

VEEV

170.52

+0.75%↑

HQY

85.25

+2.3%↑

NEOG

9.47

+1.61%↑

MDT

86.75

+0.53%↑

A

120.69

+2.16%↑

VEEV

170.52

+0.75%↑

HQY

85.25

+2.3%↑

NEOG

9.47

+1.61%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Открыт

СекторЗдравоохранение

3.44 2.08

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.35

Макс.

3.51

Ключевые показатели

By Trading Economics

Доход

-15M

-40M

Продажи

8.2M

50M

Рентабельность продаж

-80.43

Сотрудники

435

EBITDA

-19M

-42M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+14.29% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

11 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

4.2M

1.1B

Предыдущая цена открытия

1.36

Предыдущая цена закрытия

3.44

Новостные настроения

By Acuity

50%

50%

162 / 348 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

16 апр. 2026 г., 23:26 UTC

Популярные акции

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 апр. 2026 г., 20:41 UTC

Главные движущие силы рынка

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 апр. 2026 г., 23:49 UTC

Обсуждения рынка

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 апр. 2026 г., 23:45 UTC

Обсуждения рынка

Nikkei May Decline After Hitting Record High -- Market Talk

16 апр. 2026 г., 23:33 UTC

Обсуждения рынка
Главные новостные события

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 апр. 2026 г., 22:51 UTC

Обсуждения рынка

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 апр. 2026 г., 22:08 UTC

Отчет

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 апр. 2026 г., 22:06 UTC

Отчет

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 апр. 2026 г., 22:06 UTC

Отчет

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 апр. 2026 г., 22:06 UTC

Отчет

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 апр. 2026 г., 22:06 UTC

Отчет

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 апр. 2026 г., 22:06 UTC

Отчет

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 апр. 2026 г., 20:50 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

16 апр. 2026 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

16 апр. 2026 г., 20:50 UTC

Обсуждения рынка
Главные новостные события

Basic Materials Roundup: Market Talk

16 апр. 2026 г., 20:50 UTC

Обсуждения рынка
Отчет

Health Care Roundup: Market Talk

16 апр. 2026 г., 20:49 UTC

Отчет

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 апр. 2026 г., 20:43 UTC

Отчет

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 апр. 2026 г., 20:40 UTC

Обсуждения рынка
Отчет

Global Equities Roundup: Market Talk

16 апр. 2026 г., 20:40 UTC

Обсуждения рынка
Отчет

Netflix Says Engagement Quality Hits New High -- Market Talk

16 апр. 2026 г., 20:30 UTC

Популярные акции

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 апр. 2026 г., 20:25 UTC

Отчет

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 апр. 2026 г., 20:23 UTC

Отчет

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 апр. 2026 г., 20:19 UTC

Отчет

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 апр. 2026 г., 20:17 UTC

Отчет

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 апр. 2026 г., 20:17 UTC

Отчет

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 апр. 2026 г., 20:16 UTC

Отчет

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 апр. 2026 г., 20:16 UTC

Отчет

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 апр. 2026 г., 20:16 UTC

Отчет

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 апр. 2026 г., 20:16 UTC

Отчет

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Сравнение c конкурентами

Изменение цены

Maravai LifeSciences Holdings Inc (Class A) Прогноз

Целевая цена

By TipRanks

14.29% рост

Прогноз на 12 месяцев

Средняя 4 USD  14.29%

Максимум 5 USD

Минимум 3 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Maravai LifeSciences Holdings Inc (Class A) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

3

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

2.02 / 2.115Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

No Evidence

Настроения

By Acuity

162 / 348Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat